← Leaderboards

Craig Lee Slingluff

University Of Virginia

Google Scholar ↗PubMed ↗ORCID ↗

$18,119,839

Attributed

$19,911,960

Total exposure

47

Grants

36

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY2005–25

$2M$1.5M$1M$500K$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$19,911,960 · 47

By mechanism

R01$8,524,389 · 5

T32$4,107,244 · 1

M01$2,922,131 · 30

R21$2,332,990 · 4

P30$1,073,140 · 5

U01$790,816 · 1

Top collaborators

Most similar at University Of Virginia

Same institution · by research overlap

David R Brenin$407,704

Others in their field

Top investigators on “Melanoma”

David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
Richard L Schilsky · University Of Chicago$108,377,382
Larry Arthur$59,113,709
Charles A Coltman · Southwest Oncology Group$55,198,633
Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
Meenhard Herlyn · University Of Pennsylvania$46,448,742

Research focus

MelanomaResponsePeptidesClinical TrialsGrantImmune ResponseT-LymphocyteVaccinesClinical ResearchDendritic CellsFundingCd8b1 GeneVaccinationAdjuvantSourceAntigensResearch PersonnelInstitutionCellsHuman SubjectCd4 Positive T LymphocytesPeptide VaccinesTumorHuman Therapy Evaluation

Grant awards (109)

Postdoctoral Training Grant for MDs in Surgical Oncology Research$382,378

T32 · FY2025 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$272,436

T32 · FY2024 · CA · contact PI

CRX - Project$46,771

P30 · FY2024 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$303,532

T32 · FY2023 · CA · contact PI

CRX - Project$46,769

P30 · FY2023 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$309,671

T32 · FY2022 · CA · contact PI

CRX - Project$46,769

P30 · FY2022 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$316,382

T32 · FY2021 · CA · contact PI

Cancer Therapeutics Program (CRX)$37,510

P30 · FY2021 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$319,122

T32 · FY2020 · CA · contact PI

Cancer Therapeutics Program (CRX)$37,510

P30 · FY2020 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$306,896

T32 · FY2019 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$288,019

T32 · FY2018 · CA · contact PI

Antibodies to melanoma vaccine peptides$80,750

R03 · FY2018 · CA · contact PI

MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES$394,792

R01 · FY2017 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$234,982

T32 · FY2017 · CA · contact PI

Antibodies to melanoma vaccine peptides$80,500

R03 · FY2017 · CA · contact PI

MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES$394,792

R01 · FY2016 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$239,778

T32 · FY2016 · CA · contact PI

MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES$394,792

R01 · FY2015 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$236,759

T32 · FY2015 · CA · contact PI

MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES$389,386

U01 · FY2014 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$174,602

T32 · FY2014 · CA · contact PI

MELANOMA VACCINE FOR HELPER T CELLS COMBINED WITH TARGETED OR IMMUNE THERAPIES$401,430

U01 · FY2013 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$223,367

T32 · FY2013 · CA · contact PI

Melanoma vaccines using MHC-associated peptides$328,868

R01 · FY2012 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$251,565

T32 · FY2012 · CA · contact PI

Melanoma vaccines using MHC-associated peptides$328,868

R01 · FY2011 · CA · contact PI

Postdoctoral Training Grant for MDs in Surgical Oncology Research$247,755

T32 · FY2011 · CA · contact PI

Melanoma vaccines using MHC-associated peptides$339,040

R01 · FY2010 · CA · contact PI

A MULTIPEPTIDE VACCINE IN MELANOMA PATIENTS WITH EVALUATION OF INJECTION SITE$164,379

M01 · FY2010 · RR · contact PI

Tissue Procurement Facility$119,705

P30 · FY2010 · CA · contact PI

Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma$116,450

R01 · FY2010 · CA · contact PI

PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR IV MELANOMA$44,102

M01 · FY2010 · RR · contact PI

INTRATUMORAL INTERFERON GAMMA DURING VACCINATION IN METASTATIC MELANOMA$18,711

M01 · FY2010 · RR · contact PI

CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH$8,019

M01 · FY2010 · RR · contact PI

MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS$396,912

R01 · FY2009 · CA · contact PI

Melanoma vaccines using MHC-associated peptides$339,040

R01 · FY2009 · CA · contact PI

Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma$231,032

R01 · FY2009 · CA · contact PI

A MULTIPEPTIDE VACCINE IN MELANOMA PATIENTS WITH EVALUATION OF INJECTION SITE$229,101

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR$150,134

M01 · FY2009 · RR · contact PI

Tissue Procurement Facility$121,976

P30 · FY2009 · CA · contact PI

Melanoma vaccines using MHC-associated peptides$75,449

R01 · FY2009 · CA · contact PI

CLINICAL TRIAL: EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIP$40,946

M01 · FY2009 · RR · contact PI

CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH$23,398

M01 · FY2009 · RR · contact PI

MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS$387,223

R01 · FY2008 · CA · contact PI

Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma$387,080

R01 · FY2008 · CA · contact PI

Melanoma vaccines using MHC-associated peptides$339,040

R01 · FY2008 · CA · contact PI

Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab$293,721

R21 · FY2008 · CA · contact PI

EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIPANTS W/MELANOMA$240,429

M01 · FY2008 · RR · contact PI

Tissue Procurement Facility$61,177

P30 · FY2008 · CA · contact PI

CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH$25,853

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: PHASE 2: CCI-779 IN COMBINATION WITH BEVACIZUMAB IN STAGE III OR$5,171

M01 · FY2008 · RR · contact PI

CLINICAL TRIAL: EFFECTS OF LOCAL GM-CSF IN-ADJUVANT ON DENDRITIC CELLS IN MELANO$861

M01 · FY2008 · RR · contact PI

Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma$550,016

R01 · FY2007 · CA · contact PI

MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS$385,303

R01 · FY2007 · CA · contact PI

Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab$303,751

R21 · FY2007 · CA · contact PI

EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIPANTS W/MELANOMA$282,413

M01 · FY2007 · RR · contact PI

Tissue Procurement Facility$61,177

P30 · FY2007 · CA · contact PI

SYNTHETIC HELPER PEPTIDE VACCINES FOR PATIENTS WITH STAGE IV MELANOMA$32,072

M01 · FY2007 · RR · contact PI

TRANSDERMAL ADJUVANT ADMINISTRATION OF PEPTIDE-BASED VACCINE, HIGH-RISK MELANOMA$26,727

M01 · FY2007 · RR · contact PI

A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH MELANOMA$24,944

M01 · FY2007 · RR · contact PI

LEUKAPHERESIS COLLECTION OF WBC?S FROM NORMALS AND PARTICIPANTS WITH CANCER$890

M01 · FY2007 · RR · contact PI

Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma$528,059

R01 · FY2006 · CA · contact PI

MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS$388,836

R01 · FY2006 · CA · contact PI

MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES$321,561

R01 · FY2006 · CA · contact PI

TRANSDERMAL ADJUVANT ADMINISTRATION OF PEPTIDE-BASED VACCINE, HIGH-RISK MELANOMA$234,356

M01 · FY2006 · RR · contact PI

EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIPANTS W/MELANOMA$167,726

M01 · FY2006 · RR · contact PI

SYNTHETIC HELPER PEPTIDE VACCINES FOR PATIENTS WITH STAGE IV MELANOMA$100,330

M01 · FY2006 · RR · contact PI

Tissue Procurement Facility$30,588

P30 · FY2006 · CA · contact PI

EFFECT OF GM-CSF AND VACCINE SITE NUMBER ON IMMUNIZATION WITH MELANOMA PEPTIDES$19,146

M01 · FY2006 · RR · contact PI

A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH MELANOMA$15,318

M01 · FY2006 · RR · contact PI

EFFICACY OF A MELANOMA PEPTIDE VACCINE IN PATIENTS WITH ADVANCED MELANOMA$4,595

M01 · FY2006 · RR · contact PI

EFFECTS OF LOCAL GM-CSF IN-ADJUVANT ON DENDRITIC CELLS IN MELANOMA PATIENTS$765

M01 · FY2006 · RR · contact PI

MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS$411,601

R01 · FY2005 · CA

MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES$329,300

R01 · FY2005 · CA

EFFECT OF GM-CSF AND VACCINE SITE NUMBER ON IMMUNIZATION WITH MELANOMA PEPTIDES$322,205

M01 · FY2005 · RR

SYNTHETIC HELPER PEPTIDE VACCINES FOR PATIENTS WITH STAGE IV MELANOMA$58,297

M01 · FY2005 · RR

TRANSDERMAL ADJUVANT ADMINISTRATION OF PEPTIDE-BASED VACCINE, HIGH-RISK MELANOMA$29,147

M01 · FY2005 · RR

EFFICACY OF A MELANOMA PEPTIDE VACCINE IN PATIENTS WITH ADVANCED MELANOMA$7,877

M01 · FY2005 · RR

PEPTIDE VACCINE FOR PATIENTS WITH ADVANCED MELANOMA$2,363

M01 · FY2005 · RR

EFFECTS OF LOCAL GM-CSF IN-ADJUVANT ON DENDRITIC CELLS IN MELANOMA PATIENTS$787

M01 · FY2005 · RR

MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF$338,200

R21 · FY2004 · CA

VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES$338,200

R21 · FY2004 · CA

MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES$329,300

R01 · FY2004 · CA

Effect of GM-CSF And Vaccine Site Number On Immunization With Melanoma Peptides$217,441

M01 · FY2004 · RR

Immunogenicity of Vaccination with Multiple Synthetic Melanoma Peptides$90,507

M01 · FY2004 · RR

Efficacy Melanoma Peptide Vaccine for Advanced Melanoma$39,735

M01 · FY2004 · RR

Synthetic Helper Peptide Vaccines for Patients with Stage IV Melanoma$25,387

M01 · FY2004 · RR

Peptide Vaccine for Patients with Advanced Melanoma$17,659

M01 · FY2004 · RR

MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF$338,200

R21 · FY2003 · CA

VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES$338,200

R21 · FY2003 · CA

MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES$329,068

R01 · FY2003 · CA

MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES$329,300

R01 · FY2002 · CA

CORE--TISSUE PROCUREMENT FACILITY$78,870

P30 · FY2002 · CA

VACCINATION W/ MELANOMA PEPTIDES ON DENDRITIC CELLS OR W/ GMCSF IN ADJUVANT$48,533

M01 · FY2002 · RR

PULSED DENDRITIC CELLS FOR INDUCTION OF ANTITUMOR IMMUNITY IN MELANOMA PATIENTS$48,533

M01 · FY2002 · RR

AUTOLOGOUS MELANOMA CELL VACCINE WITH GMCSF AND IL2$191,359

R21 · FY2001 · CA

CORE--TISSUE PROCUREMENT FACILITY$78,870

P30 · FY2001 · CA

VACCINATION W/ MELANOMA PEPTIDES ON DENDRITIC CELLS OR W/ GMCSF IN ADJUVANT$48,533

M01 · FY2001 · RR

PULSED DENDRITIC CELLS FOR INDUCTION OF ANTITUMOR IMMUNITY IN MELANOMA PATIENTS$48,533

M01 · FY2001 · RR

AUTOLOGOUS MELANOMA CELL VACCINE WITH GMCSF AND IL2$191,359

R21 · FY2000 · CA

PEPTIDE BASED VACCINES FOR STAGE IV MELANOMA$168,667

R01 · FY2000 · CA

CORE--TISSUE PROCUREMENT FACILITY$152,724

P30 · FY2000 · CA

CORE--TISSUE PROCUREMENT FACILITY$152,724

P30 · FY2000 · CA

PULSED DENDRITIC CELLS FOR INDUCTION OF ANTITUMOR IMMUNITY IN MELANOMA PATIENTS$28,104

M01 · FY2000 · RR

VACCINATION W/ MELANOMA PEPTIDES ON DENDRITIC CELLS OR W/ GMCSF IN ADJUVANT$28,104

M01 · FY2000 · RR

VACCINATION W/ MELANOMA PEPTIDES ON DENDRITIC CELLS OR W/ GMCSF IN ADJUVANT$0

M01 · FY2000 · RR

PULSED DENDRITIC CELLS FOR INDUCTION OF ANTITUMOR IMMUNITY IN MELANOMA PATIENTS$0

M01 · FY2000 · RR